Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for protection against hepatic injury in living liver donors
PACTR202404838380059Phase 4Recruiting
- Sponsor
- National Liver Institute
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dexmedetomidine (2 arms), sponsored by National Liver Institute. Primary endpoint: Tumor necrosis factor alpha level. Started Feb 2024; status: recruiting.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on PACTR202404838380059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202404838380059.